Table 2.
Evaluation of media performance based on platform media
| Media candidatesb | Relative productivity for IgGd | Relative productivity for recombinant proteind | Cell aggregationd | Total amino acid content range (excluding glutamine)a |
|---|---|---|---|---|
| CDM1c (CDM4CHO) | Moderate | Moderate | Negligible | 2.0–3.0 |
| CDM2 (HyCell CHO) | High | High | Negligible | 4.5–5.5 |
| CDM3 (ActiPro) | High | Moderate | Negligible | 6.5–7.5 |
| CD FortiCHO | High | High | Usually observed | 7.5–9.0 |
| Cellvento CHO-210 | Low | High | Frequently observed | 3.5–4.5 |
| ExCell Advanced CHO | Moderate | Low | Negligible | 7.0–8.0 |
| PowerCHO-2 | Moderate | Poor | Usually observed | 10.5–12.5 |
aExpected ranges are from internal amino acid analysis and/or references (Reinhart et al. 2015; Carrillo-Cocom et al. 2015; Pan et al. 2017). Amino acids are detected (and reported in publications) as molar mass, so the amino acid concentration is calculated with molecular weight
bCDM4CHO (GE Healthcare, Björkgatan, Uppsala, Sweden), HyCell CHO (GE Healthcare, Björkgatan, Uppsala, Sweden), ActiPro (GE Healthcare, Björkgatan, Uppsala, Sweden), CD FortiCHO (Thermo Fisher Scientific, Waltham, MA, US), Cellvento CHO-210 (Merck KGaA, Darmstadt, Germany), ExCell Advanced CHO (SAFC Bioscience, St, Louis, Mo, USA), PowerCHO 2 (Lonza, Verviers, Belgium)
cCDM1 is an earlier commercial CHO media. The rest are recent commercial CHO media according to our classification
dThe cell lines tested here are developed from our CLD platform using CDM1, the results of each media here may be different in other cell lines